PROGRAM and ABSTRACTS

International Conference on Malignant Lymphoma
Current Status and Prospects
September 2-6, 1984
Lugano, Switzerland
PROGRAM and ABSTRACTS

International Conference on Malignant Lymphoma
Current Status and Prospects
September 2-5, 1981
Lugano, Switzerland

Chairman:
V. DeVita (Bethesda)

Advisory Board:
C. Berard (Memphis),
S. Rosenberg (Stanford)

Organizing Committee:
G. Bonadonna (Milan),
F. Cavalli (Bellinzona),
M. Rozencweig (Brussels)

Sponsored by The Swiss League Against Cancer, La Lega Ticinese Contro il Cancro, and The National Cancer Institute (Bethesda)
## INVITED PARTICIPANTS

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Banfi, Alberto</td>
<td>National Cancer Institute of Milan, Italy</td>
</tr>
<tr>
<td>Bloomfield, Clara D.</td>
<td>University of Minnesota, Minneapolis, Minnesota, USA</td>
</tr>
<tr>
<td>Berard, Costan W.</td>
<td>Division of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</td>
</tr>
<tr>
<td>Bonadonna, Gianni</td>
<td>National Cancer Institute of Milan, Italy</td>
</tr>
<tr>
<td>Brunner, Kurt W.</td>
<td>Institute for Medical Oncology, University Hospital, Inselspital, Bern, Switzerland</td>
</tr>
<tr>
<td>Crowther, Derek</td>
<td>Department of Medical Oncology, University of Manchester, Manchester, England</td>
</tr>
<tr>
<td>DeVita, Vincent T.</td>
<td>Director, National Cancer Institute, Bethesda, Maryland, USA</td>
</tr>
<tr>
<td>Fisher, Richard I.</td>
<td>National Cancer Institute, Bethesda, Maryland, USA</td>
</tr>
<tr>
<td>Fossati, Franca</td>
<td>National Cancer Institute of Milan, Italy</td>
</tr>
<tr>
<td>Frei, Emil, III</td>
<td>Director, Sidney Farber Cancer Center, Boston, Massachusetts, USA</td>
</tr>
<tr>
<td>Fuks, Zvi</td>
<td>Chairman Department of Radiation and Clinical Oncology, Hadassah University Hospital, Jerusalem, Israel</td>
</tr>
<tr>
<td>Gasparini, Marco</td>
<td>National Cancer Institute of Milan, Italy</td>
</tr>
<tr>
<td>Glatstein, Eli</td>
<td>National Cancer Institute, Bethesda, Maryland, USA</td>
</tr>
<tr>
<td>Hansen, Herbert J.</td>
<td>Memorial Sloan-Kettering Cancer Center, New York, USA</td>
</tr>
<tr>
<td>Jaffe, Elaine S.</td>
<td>National Cancer Institute, Bethesda, Maryland, USA</td>
</tr>
<tr>
<td>Jenkin, Richard D.</td>
<td>The Ontario Cancer Foundation, Toronto, Ontario, Canada</td>
</tr>
<tr>
<td>Jones, Stephen E.</td>
<td>The University of Arizona, Tucson, Arizona, USA</td>
</tr>
<tr>
<td>Kaplan, Henry S.</td>
<td>Stanford University Medical Center, Stanford, California, USA</td>
</tr>
</tbody>
</table>
Lister, Thomas A.  Department of Medical Oncology, St. Bartholomew's Hospital, London, England

Martz, Georg  Division of Oncology, University Hospital, Zürich, Switzerland

Mathé, Georges  Director, Institute of Cancerology, Villejuif, France

McElwain, T.J.  The Royal Marsden Hospital, London, England

Murphy, Sharon B.  St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Nissen, Nis I.  The Finsen Institute, Copenhagen, Denmark

Obrecht, Paul  Division of Oncology, University Hospital, Basilea, Switzerland

Peckham, M.J.  The Royal Marsden Hospital, London, England

Rappaport, Henry  City of Hope National Medical Center, Duarte, California, USA

Rilke, Franco  National Cancer Institute of Milan, Italy

Rosenberg, Saul A.  Stanford University Medical Center, Stanford, California, USA

Rozencweig, Marcel  Institute Jules Bordet, Brussels, Belgium

Salem, Philip A.  American University of Beirut Hospital, Beirut, Lebanon

Schmidt, Carl G.  Westdeutsches Tumorzentrum, Essen, West-Germany

Silvestrini, Rosella  National Cancer Institute of Milan, Italy

Tubiana, M.  Institut Gustave-Roussy, Villejuif, France

Ulmann, John E.  The University of Chicago, Chicago, Illinois, USA

Wagner, Hanspeter  Children University Hospital, Bern

Young, Robert C.  National Cancer Institute, Bethesda, Maryland, USA
## CONFERENCE SCHEDULE

**Wednesday, September 2, 1981**  
7:30 p.m. - 9:45 p.m.

### BIOLOGY AND THERAPEUTIC APPROACHES

Chairman: S. Rosenberg

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Title, Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 p.m.</td>
<td></td>
<td>WELCOME AND ANNOUNCEMENTS. F. Cavalli</td>
</tr>
<tr>
<td>7:45 p.m.</td>
<td>1</td>
<td>THE MALIGNANT LYMPHOMAS AS A HUMAN MODEL FOR THE STUDY OF NEOPLASIAS. V. DeVita. Bethesda, USA</td>
</tr>
<tr>
<td>8:15 p.m.</td>
<td>2</td>
<td>ADVANCES IN BASIC BIOLOGY RELEVANT TO A BETTER UNDERSTANDING OF HUMAN LYMPHOMAS. H. Kaplan. Stanford, USA</td>
</tr>
<tr>
<td>8:45 p.m.</td>
<td>3</td>
<td>EVOLUTION OF CLASSIFICATION OF MALIGNANT LYMPHOMAS. C. Berard. Memphis, USA</td>
</tr>
<tr>
<td>9:15 p.m.</td>
<td>4</td>
<td>THE EVOLUTION IN THE TREATMENT STRATEGY OF MALIGNANT LYMPHOMAS. G. Bonadonna. Milan, Italy</td>
</tr>
</tbody>
</table>

**Thursday, September 3, 1981**  
8:00 a.m. - 5:45 p.m.

### HODGKIN'S DISEASE - SESSION 1

Chairman: H. Kaplan

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Title, Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.</td>
<td>5</td>
<td>T-CELL INHIBITOR IN THE SERA OF UNTREATED PATIENTS WITH HODGKIN'S DISEASE. M.M. Bieber and H. Kaplan. Stanford, USA</td>
</tr>
<tr>
<td>8:20 a.m.</td>
<td>6</td>
<td>LONG TERM EFFECTS OF TOTAL LYMPHOID IRRADIATION ON THE IMMUNE SYSTEM AND ITS USE AS AN EXPERIMENTAL MODE OF IMMUNOSUPPRESSIVE THERAPY. Z. Fuks and S. Slavin. Jerusalem, Israel</td>
</tr>
<tr>
<td>8:40 a.m.</td>
<td>7</td>
<td>IMMUNOLOGIC STUDIES IN HODGKIN'S DISEASE PRIOR TO THERAPY AND AFTER PROLONGED REMISSION. R. Fisher, Ch. Vanhaelen, R. Young and V. DeVita. Bethesda, USA</td>
</tr>
<tr>
<td>9:00 a.m.</td>
<td>8</td>
<td>CHARACTERISTICS OF HODGKIN-DERIVED CELL-LINES (L 428, L 439, L 538, L 540). V. Diehl, H.H. Kirchner, M. Schaadt, H. Stein and Ch. Fonatsch. Hannover, West-Germany</td>
</tr>
</tbody>
</table>
Thursday, September 3, 1981
8:00 a.m. - 5:45 p.m. (continued)

9:15 a.m.  9 PROGNOSTIC FACTORS AND SUBGROUPS IN HODGKIN'S DISEASE. S. Rosenberg. Stanford, USA

9:35 a.m.  10 SEVERE PRURITUS: A "B" SYMPTOM IN HODGKIN'S DISEASE. P. Gobbi, G. Attardo Parrinello, G. Lattanzio, S.C. Rizzo, E. Ascari. Pavia, Italy

9:50 a.m.  COFFEE BREAK

HODGKIN'S DISEASE - SESSION 2
Chairman: H.-P. Wagner

10:10 a.m.  11 AN ANALYSIS OF 528 SCANS USING ABDOMINAL COMPUTED TOMOGRAPHY (CT) IN PATIENTS WITH LYMPHOMA. D. Crowther, G. Blackledge, H. Mamtora, J.J.K. Best and I. Isherwood. Manchester, England

10:30 a.m.  12 UPDATE ON STAGING IN HODGKIN'S DISEASE (HD). J. Ultermann, S. Neely, H. Golomb, D. Sweet, E. Lester. Chicago, USA

10:50 a.m.  13 LOW DOSE RADIATION AND MOPP CHEMOTHERAPY FOR PEDIATRIC HODGKIN'S DISEASE. H. Kaplan and S.S. Donaldson. Stanford, USA

11:05 a.m.  14 CONSERVATIVE MANAGEMENT OF CHILDHOOD HODGKIN'S DISEASE - CHEMOTHERAPY OF LOW TOXICITY, LIMITED RADIOTHERAPY AND NO LAPAROTOMY. R. Nogueira Costa, T. McElwain and A. Barrett. Sutton, England


11:30 a.m.  16 HODGKIN'S DISEASE IN CHILDREN: STAGING AND TREATMENT OF 102 CASES. F. Fossati, R. Musumeci, R. Doci, R. Giardini, C. Gianni, R. Kendi. Milan, Italy

11:50 a.m.  17 THE GERMAN COOPERATIVE STUDY FOR THE TREATMENT OF HODGKIN'S DISEASE IN CHILDREN AND ADOLESCENTS: DESIGN AND PRELIMINARY RESULTS. H. Breu, G. Schellong, E.-W. Schwarze, M. Wannenmacher. Münster, Kiel, Freiburg, West-Germany

12:00 noon  LUNCH
HODGKIN'S DISEASE - SESSION 3
Chairman: M. Peckham

1:30 p.m. 18  PRESENT STATUS OF PRIMARY CHEMOTHERAPY OF HODGKIN'S DISEASE (HD). V. DeVita. Bethesda, USA

2:00 p.m. 19  LONG TERM RESULTS OF RADIOTHERAPY. M. Peckham.
Sutton, England

2:20 p.m. 20  CLINICAL TRIALS IN HODGKIN'S DISEASE (CS I + II)
CARRIED OUT BY THE E.O.R.T.C. RADIOTHERAPY-CHEMOTHERAPY GROUP. M. Tubiana, M. Hayat,
M. Henry-Amar. Villejuif, France

2:35 p.m. 21  CHEMOTHERAPY-RADIOTHERAPY IN STAGES IB, IIn A,
IIB, III HODGKIN'S DISEASE. POSSIBILITY OF CHEMOTHERAPY REDUCTION: RESULTS OF 3 VERSUS
6 COURSES OF M.O.P.P. F. Teillet, Ch. Bayle,
B. Asselain, Ph. Lelièvre, Ch. Ferme, M. Boiron,
J. Bernard. Colombes, France

2:50 p.m. 22  MOPP CHEMOTHERAPY-SELECTIVE NODAL IRRADIATION (RT)
IN HODGKIN'S DISEASE (HD)-CLINICAL STAGES (CS)
IA-IIIB. J.-M. Andrieu, C. Bayle, F. Teillet,
J. Bernard. Paris, France

3:10 p.m. 23  EFFECTIVENESS OF NITROSOUREA (CCNU) CONTAINING 4-
DRUG PROGRAMS FOR RADIATION THERAPY FAILURES
IN ADVANCED HODGKIN'S DISEASE. M. Cooper,
T.F. Pajak, A.S. Glicksman, A.J. Gottlieb,
C.D. Bloomfield, N.I. Nissen, C.L. Spurr. Winston-
Salem, USA, for CALGB

3:25 p.m. 24  INFLUENCE OF MOPP DOSES AND TIMING ON TREATMENT
OUTCOME IN ADVANCED HODGKIN'S DISEASE (HD).
Stanford, USA

3:40 p.m.   COFFEE BREAK

HODGKIN'S DISEASE - SESSION 4
Chairman: K. Brunner

4:00 p.m. 25  SECOND MALIGNANCIES IN PATIENTS TREATED FOR HODGKIN'S DISEASE. R. Young, E.J. Glatstein, D.L. Longo,
R.I. Fisher and V.T. DeVita. Bethesda, USA
Thursday, September 3, 1981
8:00 a.m. - 5:45 p.m. (continued)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m.</td>
<td>27  FERTILITY, PREGNANCY AND PROGENY IN PATIENTS TREATED FOR HODGKIN'S DISEASE. P. Konitz, P.H. Wiernik, J. Aisner, C. Rubenz. Baltimore, USA</td>
</tr>
<tr>
<td>4:45 p.m.</td>
<td>PANEL DISCUSSION: CONTROVERSIAL ISSUES IN THE PRESENT MANAGEMENT OF HODGKIN'S DISEASE. Moderator: V. DeVita. Participants: Banfi (Milan), Bonadonna (Milan), Brunner (Bern), Nissen (Copenhagen), Peckham (London), Rosenberg (Stanford), Tubiana (Paris)</td>
</tr>
<tr>
<td>5:45 p.m.</td>
<td>ADJOURN</td>
</tr>
</tbody>
</table>

Friday, September 4, 1981
8:00 a.m. - 6:00 p.m.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. - 10:00 a.m.</td>
<td>POSTER SESSION (Room B)</td>
</tr>
</tbody>
</table>

NON HODGKIN'S LYMPHOMAS - SESSION 1
Chairman: G. Mathe

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 a.m.</td>
<td>28  IMPORTANCE OF BIOLOGIC MARKERS IN NON-HODGKIN'S LYMPHOMAS (NHL) FROM THE POINT OF VIEW OF THE PATHOLOGIST. E. Jaffe and J. Cossman. Bethesda, USA</td>
</tr>
<tr>
<td>10:20 a.m.</td>
<td>29  IMPORTANCE OF BIOLOGIC MARKERS IN NON-HODGKIN'S LYMPHOMAS (NHL) FROM THE POINT OF VIEW OF THE CLINICIAN. C. Bloomfield. Minneapolis, USA</td>
</tr>
<tr>
<td>10:40 a.m.</td>
<td>30  KINETIC AND PLOIDY CHARACTERISTICS AND THEIR CLINICAL RELEVANCE IN NON-HODGKIN'S LYMPHOMAS. R. Silvestrini, A. Costa, G. Del Bino. Milan, Italy</td>
</tr>
<tr>
<td>10:55 a.m.</td>
<td>31  CYTOKINETIC STUDIES IN THE NON-HODGKIN'S LYMPHOMAS. H. Hansen, D. Filippa, M. Andreeff, J. Valauri, B. Clarkson. New York, USA</td>
</tr>
<tr>
<td>11:10 a.m.</td>
<td>32  ORAL PRESENTATION OF MALIGNANT LYMPHOMAS. F. Rilke. Milan, Italy</td>
</tr>
<tr>
<td>11:25 a.m.</td>
<td>33  NON-HODGKIN'S LYMPHOMA OF WALDEYER'S RING. N. Masaki, H. Ikeda and Y. Shigematsu. Osaka, Japan</td>
</tr>
</tbody>
</table>
PRIMARY MALIGNANT LYMPHOMA OF WALDEYER'S RING: CLINICAL ANALYSIS OF 145 CASES. W. Tang, L. Yu and Y. Zhang. Shanghai, China

IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE - A NEW AND A DISTINCT FORM OF MALIGNANT LYMPHOMA. P. Salem, V. Nassar, Ch. Allam, S. Alami, A. Salem, K. Jabboury, L. Hashimi and M. Khalyil. Beirut, Lebanon

LUNCH

NON HODGKIN'S LYMPHOMAS - SESSION 2
Chairman: C. Schmidt


IMPLICATIONS OF STAGING AND RESTAGING OF PATIENTS WITH LYMPHOMA. S. Jones and G.E. Goodman. Tucson, USA

NEWER COMBINATION CHEMOTHERAPIES IN NON-HODGKIN'S LYMPHOMA (NHL). J. Ullmann and D.L. Sweet. Chicago, USA

CONSERVATIVE MANAGEMENT OF FOLLCULAR LYMPHOMA. T. Lister and C. Gallagher. London, England

MANAGEMENT WITH CHEMOTHERAPY ALONE OF CLINICAL STAGE I-II LYMPHOMAS OF AGGRESSIVE HISTOLOGICAL TYPE. F. Cabanillas, L.T. Campos and G.P. Bodey. Houston, USA

"AGGRESSIVE" VERSUS "MODERATE" CHEMOTHERAPY VERSUS CHEMIOIMMUNOTHERAPY FOR NON-HODGKIN'S LYMPHOMA (NHL). S. Jones. Tucson, USA

PRIMARY CHEMOTHERAPY FOR LOCALIZED DIFFUSE LYMPHOMA. S. Jones and T.P. Miller. Tucson, USA

COFFEE BREAK
NON HODGKIN'S LYMPHOMAS - SESSION 3 (Room A)
Chairman: P. Obrecht

3:45 p.m.  43  ROLE OF RADIATION THERAPY IN THE TREATMENT OF NON-HODGKIN'S LYMPHOMAS. E. Glatstein. Bethesda, USA

4:05 p.m.  44  CLINICAL TRIAL USING RADIOThERAPY AND CHEMOTHERAPY IN NON-HODGKIN'S LYMPHOMA. E.O.R.T.C. RADIOCHEMOTHERAPY GROUP. R. Somers. Amsterdam, Netherlands

4:20 p.m.  45  COMBINED MODALITY TREATMENT OF LYMPHOCYTIC AND HISTIOCYTIC LYMPHOMAS - A CALGB STUDY. H.W. Grünwald, A.S. Glicksman, N.I. Nissen, A.J. Gottlieb and T.F. Pajak. New York, Providence, Syracuse, Scarsdale (USA), Copenhagen (Denmark)

4:35 p.m.  46  AFRICAN AND AMERICAN BURKITT'S LYMPHOMA HAVE DIFFERENT CELLULAR ORIGINS: STUDIES WITH CELL LINES AND A SPECIFIC HETEROANTISERUM. I. Magrath, D. Benjamin, R. Parsons, H. Todd-Kulikowski, C. Janus. Bethesda, USA

4:50 p.m.  47  PRETREATMENT STRATIFICATION OF CHILDHOOD NON-HODGKIN'S LYMPHOMA (NHL), ACCORDING TO PRIMARY SITE, CLINICAL STAGE, AND IMMUNOPATHOLOGIC SUBTYPE: CURRENT RESULTS OF COMBINED MODALITY PROTOCOLS. S. Murphy, H.O. Hustu, G. Rivera, W.P. Bowman, G.V. Dahl. Memphis, USA


5:30 p.m.  49  THE MILAN EXPERIENCE IN THE TREATMENT OF NON HODGKIN LYMPHOMA (NHL) IN CHILDREN. M. Gasparini, F. Lombardi. Milan, Italy

5:40 p.m.  50  PROGNOSTIC FACTORS AND TREATMENT OF CNS LYMPHOMA IN ADULTS. R. Young, R.I. Fisher, D.L. Longo and V.T. DeVita. Bethesda, USA

6:00 p.m.  ADJOURN
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45 p.m.</td>
<td>51</td>
<td>J-CHAIN AS A MARKER OF B NON-HODGKIN MALIGNANT LYMPHOMAS. S. Pileri, L. Serra, M. Populizio and G. Martinei. Bologna, Italy</td>
</tr>
<tr>
<td>4:00 p.m.</td>
<td>52</td>
<td>USE OF A B-CELL SPECIFIC MONOCLONAL ANTIBODY AND CONVENTIONAL IMMUNOLOGIC MARKERS FOR TYPING OF MALIGNANT NHL. C. Christen, H.K. Forster, F.G. Gudat, J.P. Obrecht. Basilea, Switzerland</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>53</td>
<td>CLINICOPATHOLOGICAL STUDY OF 22 PATIENTS WITH B-IMMUNOBLASTIC SARCOMAS (B-IBS). D. Bron, B. Van den Heule, M. Rozencweig, H. Bondue, B. Vanderlinden and P. Strijckmans. Brussels, Belgium</td>
</tr>
<tr>
<td>4:30 p.m.</td>
<td>54</td>
<td>RESULTS OF NON HODGKIN'S LYMPHOMAS TREATMENT ACCORDING TO THE MIXED W.H.O. HISTOCYTOLOGIC AND IMMUNE CATEGORISATION. G. Mathe, J.L. Misset, M. Delgado, B. Caillou, D. Machover, P. Ribaud, C. Jasmin, M. Musset, G. Lemaigre and G. Santelli. Villejuif, France</td>
</tr>
<tr>
<td>4:45 p.m.</td>
<td>55</td>
<td>PROGNOSTIC RELEVANCE OF THE KIEL CLASSIFICATION OF NON-HODGKIN LYMPHOMAS. G. Brittinger et al, Kiel Lymphoma Study Group. Essen, West-Germany</td>
</tr>
<tr>
<td>5:00 p.m.</td>
<td>56</td>
<td>THE INTERNATIONAL FORMULATION OF THE PATHOLOGIC CLASSIFICATION OF NON HODGKIN'S LYMPHOMAS. C. Berard. Memphis, USA</td>
</tr>
<tr>
<td>5:30 p.m.</td>
<td></td>
<td>PANEL DISCUSSION CONCERNING PATHOLOGIC CLASSIFICATION OF NHL, including drs. Berard, Rappaport, Rilke</td>
</tr>
<tr>
<td>6:00 p.m.</td>
<td></td>
<td>ADJOURN</td>
</tr>
</tbody>
</table>

Friday, September 4, 1981
8:00 a.m. - 6:00 p.m. (continued)
Saturday, September 5, 1981
9:00 a.m. - 12:00 noon

**NON HODGKIN'S LYMPHOMAS - SESSION 5**
Chairman: G. Martz

<table>
<thead>
<tr>
<th>Time</th>
<th>Session No.</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m.</td>
<td>57</td>
<td>LYMPHOBLASTIC LYMPOMA AND OTHER CHILDHOOD LYMPOMAS. H. Weinstein, R. Cassidy and E. Frei III. Boston, USA</td>
<td></td>
</tr>
<tr>
<td>9:20 a.m.</td>
<td>58</td>
<td>THERAPY OF DIFFUSE HISTIOCYTIC (OH) AND UNDIFFERENTIATED (DU) LYMPHOMA WITH HIGH DOSE METHOTREXATE AND LEUCOVORIN FACTOR RESCUE (MTX/LF), BLEOMYCIN (B), ADRIAMYCIN (A), CYCLOPHOSPHAMIDE (C), ONCOVIN (O) AND DECADRON (D) (M-BACOD). A. Skarin, D. Rosenthal, G. Canellos, D. Case, J. McIntyre, G. Pinkus, W. Moloney and E. Frei. Boston, USA</td>
<td></td>
</tr>
<tr>
<td>9:35 a.m.</td>
<td>59</td>
<td>THE EPIPODOPHYLLOTOXIN VP-16-213 AS AN EFFECTIVE AGENT IN THE TREATMENT OF PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA. P. Jacobs, H.S. King and D. Dent. Cape Town, South Africa</td>
<td></td>
</tr>
<tr>
<td>9:50 a.m.</td>
<td>60</td>
<td>A RANDOMIZED TRIAL OF HIGH-DOSE CYCLOPHOSPHAMIDE, VINCristine AND PREDnisone WITH OR WITHOUT ADRIAMYCIN (CVP vs CAVP) IN ADVANCED NON-HODGKIN'S LYMPHOMAS (NHL). J.F. Bishop, P.H. Wiernik, R.S. Kaplan, M.N. Wesley, M.P. Barcos and J.C. Sutherland. Baltimore, USA</td>
<td></td>
</tr>
<tr>
<td>10:05 a.m.</td>
<td>61</td>
<td>NEW DRUGS IN MALIGNANT LYMPHOMAS. M. Rozencweig, D. Bron, D.D. Von Hoff and F.M. Wuggia. Brussels (Belgium), San Antonio, New York (USA)</td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:30 a.m.</td>
<td></td>
<td>PANEL DISCUSSION: PERSPECTIVES OF IMPROVEMENT IN THE TREATMENT OF NHL. Moderator: E. Frei. Participants: Bonadonna (Milan), Bloomfield (Minneapolis), DeVita (Bethesda), Kaplan (Stanford), Glatstein (Bethesda), Nissen (Copenhagen)</td>
<td></td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td></td>
<td>SUMMARY AND CONCLUDING REMARKS. S. Rosenberg. Stanford, USA</td>
<td></td>
</tr>
<tr>
<td>12:00 noon</td>
<td></td>
<td>ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>
The first semisynthetic vinca-alkaloid with new antitumor potential shows less neurological disturbances than vincristin.

**ELDISINE**

has been used for the treatment of various malignancies, e.g.

- acute leukemias
- blastcrisis of chronic myeloic leukemia
- malignant lymphomas